MGNX - MacroGenics MGD019 shows anti-tumor activity in advanced solid tumors

MacroGenics ([[MGNX]] -7.3%) announces clinical data from the dose escalation portion of a Phase 1 clinical trial of MGD019. The data were presented at the ESMO Virtual Congress 2020. MGD019, a bispecific PD-1 × CTLA-4 DART molecule, was designed to enhance CTLA-4 blockade on dual-expressing, tumor-infiltrating lymphocytes compared to a PD-1/CTLA-4 monoclonal antibody (mAb) combination therapy, while maintaining maximal PD-1 blockade on all PD-1-expressing cells. Forty-three patients were enrolled within a dose range of 0.03 – 10.0 mg/kg in patients with different types of solid tumors. There were no dose-limiting toxicities (DLTs).A total of 28 patients were treated at doses ? 3.0 mg/kg. MGD019 was well-tolerated in patients who received less than 10 mg/kg. In this study, sustained peripheral PD-1 blockade was evident at doses ? 1.0 mg/kg.  In addition, dose-dependent upregulation of the inducible costimulator molecule was evident in treated patients, including those who responded to MGD019 therapy. This is consistent

For further details see:

MacroGenics MGD019 shows anti-tumor activity in advanced solid tumors